首页> 美国卫生研究院文献>Frontiers in Cellular and Infection Microbiology >A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis Including Pertactin Deficient Strains
【2h】

A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against Bordetella pertussis Including Pertactin Deficient Strains

机译:百日咳外膜囊泡疫苗诱导肺驻留记忆CD4 T细胞和百日咳杆菌的保护包括缺乏百日咳杆菌粘附素的菌株。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pertussis is a respiratory infectious disease that has been resurged during the last decades. The change from the traditional multi-antigen whole-cell pertussis (wP) vaccines to acellular pertussis (aP) vaccines that consist of a few antigens formulated with alum, appears to be a key factor in the resurgence of pertussis in many countries. Though current aP vaccines have helped to reduce the morbidity and mortality associated with pertussis, they do not provide durable immunity or adequate protection against the disease caused by the current circulating strains of Bordetella pertussis, which have evolved in the face of the selection pressure induced by the vaccines. Based on the hypothesis that a new vaccine containing multiple antigens could overcome deficiencies in the current aP vaccines, we have designed and characterized a vaccine candidate based on outer membrane vesicle (OMVs). Here we show that the OMVs vaccine, but not an aP vaccine, protected mice against lung infection with a circulating pertactin (PRN)-deficient isolate. Using isogenic bacteria that in principle only differ in PRN expression, we found that deficiency in PRN appears to be largely responsible for the failure of the aP vaccine to protect against this circulating clinical isolates. Regarding the durability of induced immunity, we have already reported that the OMV vaccine is able to induce long-lasting immune responses that effectively prevent infection with B. pertussis. Consistent with this, here we found that CD4 T cells with a tissue-resident memory (TRM) cell phenotype (CD44+CD62LlowCD69+ and/or CD103+) accumulated in the lungs of mice 14 days after immunization with 2 doses of the OMVs vaccine. CD4 TRM cells, which have previously been shown to play a critical role sustained protective immunity against B. pertussis, were also detected in mice immunized with wP vaccine, but not in the animals immunized with a commercial aP vaccine. The CD4 TRM cells secreted IFN-γ and IL-17 and were significantly expanded through local proliferation following respiratory challenge of mice with B. pertussis. Our findings that the OMVs vaccine induce respiratory CD4 TRM cells may explain the ability of this vaccine to induce long-term protection and is therefore an ideal candidate for a third generation vaccine against B. pertussis.
机译:百日咳是一种呼吸道感染性疾病,在过去的几十年中已被治愈。从传统的多抗原全细胞百日咳(wP)疫苗到由几种用明矾配制的抗原组成的无细胞百日咳(aP)疫苗的转变,似乎是许多国家百日咳病复发的关键因素。尽管当前的aP疫苗有助于降低与百日咳有关的发病率和死亡率,但它们不能提供持久的免疫力或对因百日咳博德特氏菌目前流行的菌株引起的疾病的足够保护,而这种菌株是在面对由百日咳杆菌引起的选择压力后演变而来的。疫苗。基于这样的假设,即一种含有多种抗原的新疫苗可以克服当前aP疫苗的缺陷,我们设计并表征了基于外膜囊泡(OMV)的候选疫苗。在这里,我们显示OMVs疫苗而非aP疫苗可保护小鼠免受循环pertactin(PRN)缺陷型分离株的肺部感染。使用原则上仅在PRN表达上不同的等基因细菌,我们发现PRN​​的缺乏似乎是造成aP疫苗无法抵抗这种循环临床分离株的主要原因。关于诱导免疫的持久性,我们已经报道了OMV疫苗能够诱导持久的免疫反应,从而有效地预防百日咳博德特氏菌的感染。与此相符的是,我们在这里发现具有组织驻留记忆(TRM)细胞表型(CD44 + CD62L low CD69 + 和/或CD103 + )在用2剂OMV疫苗免疫后14天累积在小鼠的肺中。 CD4 TRM细胞先前已被证明在持续抵抗百日咳博德特氏菌的保护性免疫中起关键作用,在用wP疫苗免疫的小鼠中也检测到CD4 TRM细胞,但在商业aP疫苗免疫的动物中未检测到CD4 TRM细胞。百日咳博德特氏菌小鼠呼吸激发后,CD4 TRM细胞分泌IFN-γ和IL-17,并通过局部增殖而显着扩增。我们的OMV疫苗诱导呼吸道CD4 TRM细胞的发现可能解释了该疫苗诱导长期保护的能力,因此是抗百日咳博德特氏菌第三代疫苗的理想候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号